Trelagliptin succinate A tert-Butyl ester LY3009120 showed activities against BRaf

LY3009120 showed activities against BRaf or Ras mutant tumor cells

a tyrosyl-DNA phosphodiesterase I inhibitor from an Australian fungus of the family Cortinariaceae

Molecular Weight: 181

PubMed PMID: 26530115

Chemical Name: 3-chloro-N-((1r

Trelagliptin succinate A tert-Butyl ester LY3009120 showed activities against BRafTrelagliptin, also known as SYR 472, is a long acting dipeptidyl peptidase 4 (DPP 4) inhibitor that is being developed by Takeda for the treatment of type 2 diabetes (T2D). Once weekly SYR 472 treatment produced clinically and statistically significant improvements in glycaemic control in patients with type 2 diabetes. It was well tolerated and might be a new treatment option for patients with this disease. Trelagliptin (Zafatek()) was approved in